logo
logo

Kahr Announces $46.5 Million Financing To Advance Its Multifunctional Immunotherapeutic Pipeline

Jun 16, 2021•about 4 years ago

Amount Raised

$46.5 Million

Jerusalem

Description

KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced the first closing of an investment round raising $46.5 million. The financing was led by aMoon with participation from new investors BVF Partners LP, DAFNA Capital Management LLC, Peregrine Ventures, Shavit Capital and the Cancer Focus Fund. Existing investors also participated in this financing, including Flerie Invest AB, Oriella Limited (CBG, chaired by Vincent Tchenguiz), Pavilion Capital, Hadasit Bio Holdings Ltd (HBL) and Mirae Asset.

Company Information

Company

Kahr

Location

Jerusalem, Jerusalem District, Israel

About

KAHR is developing the next generation of immuno-oncology drug candidates for the treatment of multiple types of cancer. The Company's lead product candidate, DSP107, is a first-in-class CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses and activates an effective, local response of both innate and adaptive immunity. KAHR's technology platform is based on multi-functional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells to selectively target and bind to the tumor. MIRPs bridge cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response, while recruiting the adaptive immune system to bind and selectively kill the cancer cells. For more information, please visit kahrbio.com/.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech